Medication info

Entiruvatine Tablet 10mg (Rosuvastatin Calcium)

Prescription medicationTabletExpired
Ingredient · strength
Rosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Korea Sintex Pharmaceuticals Co., Ltd.
Appearance
Pink round film-coated tablet
Packaging
30 tablets/PTP [(15 tablets/PTP x 2 pieces)]
Approval status
Expired

MFDS item code 201908118 · Approved 2019.11.27

This product's status changed to Expired on 2024.11.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease
Who uses it
Adults · Children
Adult dosage
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to achieve control in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 milligrams daily. 3. Older adults: Dose adjustment is not necessary. 4. Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.
Children's dosage
2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Ingredients

Manufacturer
Korea Sintex Pharmaceuticals Co., Ltd.

Efficacy & effects

Improvement of dyslipidemia, inhibition of atherosclerosis progression, and prevention of cardiovascular disease

  • Primary hypercholesterolemia
  • mixed dyslipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL-cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used as an adjunctive treatment for patients with primary hypercholesterolemia and mixed dyslipidemia that is not controlled by dietary changes and exercise. It is also used in conjunction with diet or other lipid-lowering therapies for patients with homozygous familial hypercholesterolemia, helping to lower total cholesterol and LDL-cholesterol levels, thereby delaying the progression of atherosclerosis. Particularly, it reduces total cholesterol and LDL-cholesterol levels as an adjunctive treatment to diet in pediatric patients aged 10 to 17 years with heterozygous familial hypercholesterolemia. It is also used as an adjunct to diet in patients with primary dysbetalipoproteinemia and contributes to reducing the risks associated with stroke, myocardial infarction, and arterial revascularization in adults at high risk of cardiovascular disease. Thus, it is effectively used in various types of dyslipidemia and for risk reduction of cardiovascular diseases.

Dosage and Administration

Adult dosage

1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, regardless of meals. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is required, the dose may be adjusted as a maintenance dose. The maintenance dose is 10 milligrams once daily, which is sufficient to achieve control in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to LDL cholesterol levels, treatment goals, and patient response, and may be increased up to a maximum of 20 milligrams daily. 3. Older adults: Dose adjustment is not necessary. 4. Patients with renal impairment: Dose adjustment is not necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Exercise particular caution when administering 20mg of this drug to patients with moderate renal impairment. 5. Patients with hepatic impairment: Although no increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 6. Race: Because systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40-milligram dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40-milligram dose is contraindicated in some of these patients.

Children's dosage

2. Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dosage range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses greater than 20 milligrams in pediatric patients.) The dose should be individually adjusted according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or longer. Children under 10 years: Safety and efficacy have not been established.

Precautions

This medication should not be used in patients with known allergies to specific ingredients. Patients with severe liver dysfunction or elevated liver enzymes of unknown cause should avoid this medication. Patients with muscle disorders or problems with muscle should not take this medication. Those taking certain immunosuppressants, and patients with severe renal impairment should also avoid this medication. Pregnant or breastfeeding women, and fertile women not using proper contraception should not take this medication. Patients at risk of muscle disorders should avoid high doses and should be cautious if they have renal impairment, hypothyroidism, or a history of genetic muscle diseases. Patients with genetic metabolic disorders such as lactose intolerance should also not take this medication. Patients who consume large amounts of alcohol or have a history of liver disease should undergo frequent liver function tests, and other conditions such as hypothyroidism should be treated first. If symptoms like muscle pain, weakness, or cramps occur, the doctor should be informed immediately, and blood tests may be required to check for muscle damage. Patients at risk of severe muscle damage should check their muscle enzyme levels before starting treatment and should not take the medication if levels are elevated. This medication may rarely cause severe skin reactions or liver dysfunction; therefore, if symptoms such as skin rash or jaundice appear, use should be stopped immediately. This medication may interact with other drugs; thus, any medications being taken should be reported to a doctor or pharmacist. In the case of overdose, there is no specific antidote, so treatment should be symptomatic and liver function and muscle enzyme tests are necessary. Caution is advised when driving or operating machinery as dizziness may occur. During pregnancy, this medication may be harmful to the fetus, so it should not be taken if planning to become pregnant or if already pregnant. It is important to regularly check blood tests and liver function tests during the use of this medication for any abnormalities.

Side effects

Allergic reactions, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular myasthenia, thrombocytopenia, jaundice, hepatitis, elevated transaminases, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lichenoid drug rash, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive decline, forgetfulness, amnesic syndrome, memory impairment, confusion, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, paresthesia, chest discomfort, loss of appetite, abdominal distension, fainting, generalized pain, fatigue

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to protect it from air and moisture, and it is safe to keep it at room temperature between 1 degree and 30 degrees Celsius. Therefore, avoid excessively cold or hot places, and it is advisable to keep it in a cool place away from direct sunlight.

Appearance and packaging

Appearance

Pink round film-coated tablet

Package unit

30 tablets/PTP [(15 tablets/PTP x 2 pieces)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.